Investment Rating - The investment rating for Giant Biogene Holding is "Buy" with a 12-month price target of HK$71, representing an upside of 31.7% from the current price of HK$53.90 [12]. Core Insights - Despite recent uncertainties, Giant Biogene has reiterated its FY25 guidance, expecting sales and net income to grow by 25-28% and 21-24% year-on-year, respectively, with projected figures of RMB6.9-7.1 billion in sales and RMB2.5-2.6 billion in net income [1][3]. - The company is focusing on customer acquisition and retention through enhanced marketing strategies, including increased sample gifts and differentiated product bundles [10]. - Management anticipates a gradual recovery in KOL livestreaming, which has been a significant factor in recent sales pullbacks, and plans to enhance consumer trust through transparency initiatives [1][10]. Summary by Sections Financial Performance - FY25 guidance remains unchanged with sales expected to be between RMB6.9-7.1 billion and net income between RMB2.5-2.6 billion, reflecting a year-on-year growth of 25-28% and 21-24% respectively [1][3]. - The stock is currently trading at 20x 2025E PE based on the company's guidance, which is considered attractive given the expected recovery in the latter half of FY25 [2]. Sales Drivers - The company has reported strong performance in offline sales channels, with 1H25 growth exceeding initial expectations, and minimal impact from recent allegations on overall sales [9][10]. - Specific sales initiatives include increasing sample gifts and providing exclusive benefits to enhance customer loyalty [10]. Market Position and Strategy - Giant Biogene is actively working on improving brand perception through transparency initiatives, public welfare activities, and partnerships with medical institutions [10]. - The approval processes for medical aesthetics (MA) are proceeding smoothly and are not expected to be affected by recent uncertainties [10].

Investment Rating - The investment rating for China Medical System Holdings is "Buy" with a 12-month price target of HK$12.57, indicating an upside potential of 2.4% from the current price of HK$12.28 [8][16]. Core Insights - The company anticipates double-digit sales growth for 2025 and positive topline growth for 2026 following the spin-off of its dermatology subsidiary, Dermavon [1][2]. - Key drivers for growth include the expected doubling of new drug sales post NRDL listing, resumption of growth for Xinhuosu, and stable performance of three core drugs [2][6]. - Two potential blockbuster products are highlighted: Y-3 for stroke with peak sales potential exceeding Rmb3 billion and ABP-671 for gout, which is expected to have better safety profiles compared to current standards of care [2][6]. Summary by Sections Sales Growth and Spin-off - The company maintains its guidance for double-digit sales growth in 2025, with positive growth expected in 2026 after the completion of Dermavon's spin-off by the end of 2025 [1][2]. - Growth drivers include new drug sales, diversified hospital coverage for Xinhuosu, and stable performance of core drugs [2][6]. Product Pipeline - The dermatology portfolio has a peak sales potential exceeding Rmb15 billion, with specific products like tildrakizumab targeting Rmb2 billion and ruxolitinib cream targeting at least Rmb6 billion [3][6]. - Other notable products include povorcitinib and comekibart, both with significant sales potential in their respective indications [6]. Financial Projections - Revenue projections for the upcoming years are as follows: Rmb7,469 million for 2024, Rmb8,244 million for 2025, and Rmb9,580 million for 2026 [8]. - The company is expected to maintain a stable EBITDA margin, with projected EBITDA of Rmb2,193 million in 2024 and Rmb2,982 million in 2026 [8].

Investment Rating - The investment rating for WuXi XDC is Neutral with a 12-month price target of HK$39.00, indicating a downside potential of 7.6% from the current price of HK$42.20 [8]. Core Insights - WuXi XDC's management reiterated a high visibility for FY25 revenue growth guidance of over 35% year-on-year, driven by strong client demand in ADC development, particularly from emerging biotech companies in China [2][6]. - The company maintains technological leadership in ADC and bio-conjugates, with a diversified technology platform that includes various payloads and linkers, and a significant portion of new projects stemming from novel molecules [2][6][7]. - Capacity expansion is on track, with the Singapore site expected to start operations by the end of 2025 and GMP release anticipated in 2026, supported by a capital expenditure allocation of Rmb1.4 billion for FY25 [7]. Summary by Sections Revenue Growth and Client Demand - WuXi XDC expects over 35% revenue growth in FY25, supported by robust client demand in ADC development, with 60% of large-scale out-licensing deals in 2024 coming from its client base [2][6]. - The company has partnered with 13 of the top 20 global pharmaceutical companies, contributing 32% of its revenue [6]. Technological Leadership - WuXi XDC continues to expand its capabilities in ADC and bio-conjugates, with 35% of new projects in 2024 involving novel molecules, totaling 4,200 molecules, including 2,800 in ADCs [6][7]. - The company holds the number one position globally in terms of the number of global IND approvals in 2024 [7]. Capacity Expansion - The Singapore site is set to begin operations by the end of 2025, with a gradual capacity release strategy to manage depreciation and amortization impacts [7]. - The Wuxi DP3 line is expected to launch in the second half of 2025, while the DP5 line is under design and targeted for operation by the end of 2027 [7].

Investment Rating - The report assigns a Buy rating to BYD Co. and a Sell rating to SAIC Motor [9][13]. Core Insights - The China NEV industry is experiencing a slowdown in capacity expansion, with net additions expected to be 2.5 million units in 2025, a 13% year-over-year increase, followed by further declines in subsequent years [1]. - Capital expenditure (capex) expectations for 2025 have increased due to stronger demand driven by trade-in subsidies, while 2026 capex remains stable [2]. - The cost curve has steepened between different groups of OEMs, with group 1 players managing better EBITDA margins compared to groups 2 and 3 amid intensified competition [3]. - Demand for NEVs is projected to rise by 11% in 2024 compared to previous expectations, with significant contributions from trade-in subsidies [6]. - Utilization rates are expected to improve in 2025-2026 but may decline in 2027-2028, leading to potential consolidation in the industry [7][8]. Summary by Sections Industry Capacity and Capex - NEV capacity in China is still expanding but at a slower pace, with net additions of 2 million and 1.5 million units expected in 2026 and 2027, respectively [1]. - Market expectations for capex have increased due to positive outlooks from OEMs, driven by trade-in subsidies [2]. Cost and Profitability - OEMs are facing lower EBITDA margins due to increased competition, with group 1 players showing better cost control compared to groups 2 and 3 [3]. - The cash conversion cycle is tightening, indicating deteriorating cash flow for many players [5]. Demand and Market Dynamics - Domestic NEV demand is expected to reach 10.9 million and 14.1 million units in 2024 and 2025, respectively, with a portion stimulated by trade-in subsidies [6]. - The NEV market is highly competitive, with transaction prices declining by 6% year-over-year in early 2025 [7]. Future Outlook - A potential decline in retail PV volume is anticipated in 2027, leading to a 1% decrease in NEV volume demand despite higher penetration [7]. - The report suggests that consolidation in the industry may begin in 2027-2028, with a positive turnaround expected post-consolidation starting from 2029 [8].

Investment Rating - The report assigns a "Buy" rating to Longi and "Neutral" ratings to Daqo and Xinjiang Daqo New Energy, while TZE and Tongwei are rated as "Sell" [28][17][20]. Core Insights - The profitability inflection for the solar industry is expected to be delayed due to slower demand growth, with normalized earnings projected to remain low. The industry is anticipated to reach a cyclical bottom in 2025E, with a demand growth slowdown in China expected to average +6% CAGR from 2025E to 2030E, compared to +55% from 2020 to 2024 [1][15]. - The report highlights that the solar industry's capacity utilization is expected to decline to 59% from 2025E to 2030E, which is 15 percentage points lower than previous estimates. This is attributed to existing capacity cuts and a deceleration in demand growth [10][15]. - The report emphasizes the importance of a healthy balance sheet and strong R&D capabilities for companies navigating the cyclical bottom of the industry [1][14]. Industry Capex Trend and Capacity Addition - Capex spending in the solar industry is projected to decline further, with a forecasted -55% year-over-year decrease in solar capex for 2025E, compared to a previous estimate of -34% [2]. - The report notes that 30GW of module capacity has been terminated, including 15GW by Longi, and 12GW of module capacity has been delayed from listed players [2]. Demand Dynamics - Solar demand growth is expected to slow significantly, with a projected 25% decrease in global demand from 2026E to 2030E compared to previous estimates. This is primarily due to new regulations that limit on-grid access for large-scale solar projects and remove guaranteed on-grid volumes and prices for renewable projects [7]. - The report anticipates a rebound in China’s demand by 14% year-over-year in 2027E after a decline of -17% in 2026E, driven by better economics for commercial and industrial battery energy storage systems [7]. Capacity and Utilization - The report estimates a 17% cut in end-2024 module capacity by the end of 2026E, influenced by market access constraints and cash burn [3][10]. - The capacity utilization in China is projected to be 53% in 2025E and 52% in 2026E, with a slight recovery to 59% by 2027E [8]. Company-Specific Insights - Longi is highlighted as a leading integrated module player with strong R&D capabilities, expected to benefit from upstream price contractions and improved ROE due to Back Contact technology [16][17]. - TZE is rated as "Sell" due to anticipated headwinds from a shrinking addressable market and a stretched balance sheet amid aggressive downstream investment plans [19][20].

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies within the coverage Core Insights - The report discusses the impact of recent regulations on the blind box market, particularly focusing on the exposure of companies like Pop Mart, Bloks, Miniso, and Shanghai M&G to these regulations [1][2] - It highlights that companies with a more adult-skewed customer base and better control over distribution channels are less likely to be negatively impacted by the regulations [2] - The report emphasizes the importance of diversifying product offerings to mitigate risks associated with the blind box category [2] Summary by Relevant Sections Regulatory Impact - On June 20, People's Daily published an article addressing issues related to blind box purchases, particularly among minors, which led to a decline in share prices for companies in the coverage [1][3] - The article noted irrational consumption among minors and recommended stricter regulations, including age restrictions and guardian approval for purchases by minors over 8 years old [3][7] Company Exposure - Pop Mart and Bloks derive a significant portion of their revenue from blind box products, with Bloks having 63% of its revenue from this category in 2023 [2][8] - Miniso and Shanghai M&G have relatively lower exposure to blind box sales, with Miniso's toy category accounting for around 30% of its revenue [2][11] Market Sentiment and Valuation - The report indicates that regulatory news typically has a short-term negative impact on stock prices, but the long-term effects are often mitigated by strong fundamentals and earnings performance [2][8] - Historical data shows that share prices of Pop Mart and Miniso have rebounded after previous regulatory announcements, suggesting that market sentiment can recover quickly under favorable conditions [14][22] Company-Specific Strategies - Pop Mart targets an adult customer base, which may help it manage the impact of regulations, while also expanding its product offerings to include items beyond blind boxes [9][22] - Miniso's diversified product strategy and retail partner model in China help it maintain compliance and mitigate risks associated with specific categories [9][10] - Bloks faces challenges due to its high exposure to the blind box category and a distribution-heavy sales model, which may require more effort to ensure compliance with regulations [10][19] Financial Projections - The report provides sensitivity analyses for Bloks, indicating potential earnings downside risks of 15%-38% if sales from kids-related blind boxes decline significantly [10][19] - For Pop Mart, earnings forecasts have been revised upward for 2025-2027, reflecting strong growth momentum in both domestic and international markets [22][23]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - Soft data has historically indicated economic slowdowns earlier than hard data, but current hard data may take longer to reflect the impact of tariffs due to frontloading of imports and spending [3][6] - Surveys and management commentary can still provide valuable insights if interpreted carefully, focusing on concrete company decisions rather than general economic impressions [4][8] - The overall commentary suggests a forecast of slower hiring, slightly higher unemployment, minimal growth in investment spending, below-potential GDP growth, and a one-time inflation rebound to the mid-3s [4][46] Hiring Insights - Companies affected by policy uncertainty and reliant on sales to China and Europe have significantly reduced job openings, while total openings have only moderately declined [12][13] - The share of companies signaling layoffs has increased slightly, but remains low compared to historical peaks, and hiring freezes have risen but are still within expansion period ranges [14][19] Investment Insights - Analysts have lowered capital spending expectations for more companies than they have raised in the last three quarters, although total capital expenditure expectations have risen due to increased AI investment [20][22] - Companies most affected by tariffs and policy uncertainty have seen larger reductions in capital spending expectations, with a notable 5-6% decrease for those with significant sales exposure to China and the EU [22][27] Production and Supply Chain Insights - Companies are increasingly concerned about tariffs impacting their supply chains but have not reported significant shortages that could disrupt production [28][31] - The report assumes that tariffs will not lead to widespread shortages, which could otherwise pose risks to inflation and GDP growth [32] Pricing Insights - Companies have announced only modest price increases this year, with expectations that consumers will absorb about 50% of the direct tariff costs, lower than the previously assumed 70% [4][43] - The limited increase in price announcements reflects a cautious approach among companies, particularly those exposed to policy uncertainty [33][38]

Investment Rating - The report maintains a "Buy" rating for several companies including NAURA, SICC, SUMCO, Shin-Etsu Chemical, Mitsubishi Electric, and Infineon [2]. Core Insights - The report highlights significant growth in local production and demand for silicon wafers and SiC substrates in China, with local coverage expected to increase from 41% to 54% for 12-inch silicon wafers and from 80% to 87% for 6-inch SiC substrates by 2027E [1][6]. - Pricing trends indicate a decline in average selling prices (ASP) for 8-inch silicon wafers at a CAGR of -10% from 2024 to 2026E, while 12-inch wafers are expected to decline at -6% CAGR during the same period. SiC substrate ASP is projected to decrease from US$443 in 2024 to US$384 in 2026E [1][6]. - Capacity expansion is notable, with 12-inch silicon wafer capacity expected to grow at a CAGR of 21% from 2024 to 2027E, significantly outpacing the 3% CAGR for 8-inch silicon wafers. SiC substrate capacity is also set to expand at 26% and 96% CAGR for 6-inch and 8-inch substrates, respectively [1][6]. - The report anticipates a consolidation in the industry, with the top three Chinese silicon wafer suppliers projected to cover 36% of domestic demand by 2027E, up from 26% in 2024 [1]. Summary by Sections China TAM - The total addressable market (TAM) for silicon wafers in China is projected to grow from US$1.999 billion in 2021 to US$4.511 billion by 2030E, with a notable increase in shipments from 36,962k units in 2021 to 103,570k units by 2030E [37]. - The SiC substrate market is expected to grow from US$197 million in 2021 to US$2.770 billion by 2030E, driven by rising EV penetration and SiC adoption rates [39]. - The GaN devices market is projected to expand from US$66 million in 2021 to US$1.611 billion by 2030E, supported by applications in EVs, data centers, and consumer electronics [42]. Supply and Demand Dynamics - Local suppliers' capacity expansion in silicon wafers is primarily driven by logic and memory clients, while SiC substrate capacity is expanding due to increased adoption in EVs and fast charging technologies [43]. - The report notes that local suppliers are expected to cover 75% of SiC substrate demand in China by 2025E, increasing to 84% by 2027E [6][39]. - The demand for SiC and GaN is anticipated to replace IGBT in high power and high frequency applications, with SiC penetration rates projected to reach 75% in EVs by 2030E [52]. Pricing Trends - The ASP for silicon wafers is expected to decline, with 8-inch wafers decreasing at a CAGR of -10% and 12-inch wafers at -6% from 2024 to 2026E [1][6]. - SiC substrate pricing is also expected to narrow, making SiC MOSFETs more competitive against silicon IGBTs [1]. Industry Consolidation - The report indicates a trend towards consolidation in the silicon wafer industry, with the top three suppliers expected to significantly increase their market share in China by 2027E [1].

Investment Rating - The report assigns a Neutral rating to Tesla Inc. with a 12-month price target of $285, indicating a potential downside of 18.3% from the current price of $348.68 [16][19]. Core Insights - The launch of Tesla's robotaxi operations is seen as a significant step towards addressing the autonomous vehicle (AV) rideshare market, with an estimated market size of approximately $7 billion in the U.S. by 2030 [13]. - Initial user feedback on the robotaxi rides has been largely positive, highlighting smooth driving experiences, although some navigation issues were reported [4][6]. - The comparison with Waymo indicates that Tesla's operational area and service hours are currently more limited, which may affect its competitive positioning in the AV market [7][10]. Summary by Sections Robotaxi Launch Performance - Initial rides have shown a good degree of drive smoothness, with users noting features like a customer support button and personalized preferences [4][6]. - A navigation error was reported where a vehicle incorrectly used a left turn lane, raising concerns about the technology's readiness [6][10]. Comparison with Waymo - Tesla's robotaxi operates in a smaller area and has limited hours (6 am to midnight) compared to Waymo's 24/7 service in a larger operational area [7][10]. - Pricing for Tesla's rides is set at a flat fee of $4.20, while Waymo's pricing varies like traditional Uber rides [7]. Scaling and Future Outlook - The presence of a Tesla employee in the vehicle and the reported navigation issues suggest that scaling will be slow in the near term [10]. - Regulatory developments will be crucial for the speed of scaling, with Texas recently signing a bill requiring permits for robotaxi operations [11]. - The report includes a discounted cash flow (DCF) analysis for Tesla's robotaxi business, indicating a wide range of potential value per share depending on scaling and margin differentiation [14][16].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The China Current Activity Indicator (CAI) decreased to +4.3% month-on-month annualized seasonally adjusted in May from +4.6% in April, indicating a slight slowdown in economic activity [7] - The weakening in CAI was primarily driven by the manufacturing sector, suggesting challenges in this area [12] - The import-implied domestic demand proxy indicates largely stable growth in recent months, reflecting resilience in domestic consumption [9] - The Financial Conditions Index (FCI) eased in May, mainly due to foreign exchange depreciation against a trade-weighted basket, which may impact liquidity conditions [27][24] - The report anticipates a faster pace of government bond issuance in the coming months, with an additional RMB1 trillion quota expected to be approved [36] Summary by Relevant Sections Economic Indicators - The CAI fell to +4.3% in May, down from +4.6% in April, indicating a deceleration in economic momentum [7] - Manufacturing and construction growth proxies both declined in May, highlighting sector-specific weaknesses [13] Domestic Demand - The import-implied domestic demand proxy suggests stable growth, indicating that domestic consumption remains resilient despite external pressures [9] Financial Conditions - The FCI eased in May, primarily driven by FX depreciation, which may affect overall economic liquidity [27][24] - The growth impact of FCI impulse is expected to turn positive from Q2 onwards, suggesting potential recovery in economic activity [12] Government Policy - The report notes a slight tightening in the domestic macro policy proxy in May, driven by a narrower fiscal deficit, which may influence future economic stimulus measures [35] - An increase in government bond issuance is projected, with expectations of an additional RMB1 trillion quota to be approved [36]